The FDA has approved Neurocrine Bioscience’s Ingrezza, the first ever licensed treatment for tardive dyskinesia or TD. The condition is characterised by uncontrollable movement of the body or ...

The payer coverage changes suggests gradually increasing stringency around Ingrezza utilization, which may help explain Q4 weakness and the company’s disappointing FY25 guidance, the analyst ...

The firm sees potential upside for Neurocrine shares with multiple commercial products, including Ingrezza and Crenessity, and late stage programs in schizophrenia and depression, the analyst ...

EU countries have agreed on a market correction mechanism which will limit episodes of extraordinarily high gas prices in the EU and thus reduce the impact of price hikes on citizens and the economy.

Competition to Austedo and Xenazine is also looming from Neurocrine Biosciences, whose VMAT2 drug Ingrezza (valbenazine) is already approved to treat tardive dyskinesia with a phase 3 readout in ...

The medicines that can treat more serious symptoms include: Deutetrabenazine (Austedo) Valbenazine (Ingrezza) Your doctor may also use an off-label medicine called tetrabenazine (Xenazine).

Neurocrine Biosciences (Nasdaq: NBIX) has announced positive results from its Phase IV KINECT-PRO study, showing that Ingrezza (valbenazine) provided meaningful and sustained benefits for patients ...

After hours: March 17 at 4:20:00 PM EDT Loading Chart for NBIX ...

The Social Security program serves as a financial lifeline for approximately 69 million Americans, including retirees, disabled individuals, and survivors. Recent developments involving the Department ...